<H1>Chapter DOI: 10.1007/978-1-60327-829-4_19<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>48</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>46</td></tr><tr><td>BibStructured Count</td><td width="10%">34</td></tr><tr><td>BibUnstructured Count</td><td width="10%">14</td></tr><tr><td>DOI already available in SpringerLink</td><td>27</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>2</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_19</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Giving Thalidomide a Second <span style='background:#CCFF99'>Chance</span></span>. <span style='background:#66FF66'>1997</span>. (Accessed August 18, 2008, at <span style='background:#FF3300'>http://www.fda.gov/fdac/features/1997/697_thal.html</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_19</td><td>BibArticle</td><td>D&#8217;Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082&#8211;5.</td><td><a href=http://dx.doi.org/10.1073/pnas.91.9.4082>10.1073/pnas.91.9.4082</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_19</td><td>BibArticle</td><td>Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827&#8211;34.</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(98)00046-X>10.1016/S0006-2952(98)00046-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_19</td><td>BibArticle</td><td>Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 2006;7:677&#8211;85.</td><td><a href=http://dx.doi.org/10.2174/138920006778017777>10.2174/138920006778017777</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_19</td><td>BibArticle</td><td>Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001;35:437&#8211;52.</td><td><a href=http://dx.doi.org/10.1080/003655901753367532>10.1080/003655901753367532</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_19</td><td>BibArticle</td><td>Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545&#8211;51.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19950515)75:10&lt;2545::AID-CNCR2820751022&gt;3.0.CO;2-X>10.1002/1097-0142(19950515)75:10&lt;2545::AID-CNCR2820751022&gt;3.0.CO;2-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_19</td><td>BibArticle</td><td>Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J.Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_19</td><td>BibUnstructured</td><td>S.T.E.P.S. System for Thalidomide Education and Prescribing Safety. (Accessed August 18, <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>http://www.thalomid.com/steps_program.aspx</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9_19</td><td>BibArticle</td><td>Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888&#8211;93.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dixon</span> <span style='background:#DDDDDD'>SC</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kruger</span> <span style='background:#DDDDDD'>EA</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bauer</span> <span style='background:#DDDDDD'>KS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Figg</span> <span style='background:#DDDDDD'>WD.</span></span></aug>, <span style='background:#CCCCFF'>Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells</span>. <span style='background:#CCFF99'>Cancer Chemother Pharmacol</span> <span style='background:#66FF66'>1999</span>;43 <span style='background:#D279FF'>Suppl:S78&#8211;84</span>.</td><td><a href=http://dx.doi.org/10.1007/s002800051103>10.1007/s002800051103</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Year, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR11_19</td><td>BibArticle</td><td>Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001;24:1050&#8211;7.</td><td><a href=http://dx.doi.org/10.1002/mus.1109>10.1002/mus.1109</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_19</td><td>BibArticle</td><td>Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6600817>10.1038/sj.bjc.6600817</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_19</td><td>BibArticle</td><td>Figg WD, Hussain MH, Gulley JL, et al. A double blind randomized crossover study of oral thalidomide versus placebo in patients with androgen dependent prostate cancer treated by intermittent androgen ablation. J Urol 2009;181(3):1104&#8211;13.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2008.11.026>10.1016/j.juro.2008.11.026</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_19</td><td>BibArticle</td><td>Efstathiou E, Troncoso P, Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007;13:1224&#8211;31.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-1938>10.1158/1078-0432.CCR-06-1938</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_19</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_19</td><td>BibArticle</td><td>Petrylak DP, Macarthur RB, O&#8217;Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958&#8211;67.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_19</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_19</td><td>BibArticle</td><td>Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26:14&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_19</td><td>BibArticle</td><td>Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532&#8211;9.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.05.074>10.1200/JCO.2004.05.074</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_19</td><td>BibArticle</td><td>Figg WD, Li H, Sissung T, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007;99:1047&#8211;55.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2007.06763.x>10.1111/j.1464-410X.2007.06763.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_19</td><td>BibArticle</td><td>Frank R, Versea L, Cohen N, Long J, Nair K. Low-dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide in androgen-independent prostate cancer (AIPC): final results of a phase II community based study in elderly men. J Clin Oncol 2007;25:15609.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22_19</td><td>BibArticle</td><td>Mathew P, Logothetis CJ, Dieringer PY, et al. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 2006;5:144&#8211;9.</td><td><a href=http://dx.doi.org/10.3816/CGC.2006.n.031>10.3816/CGC.2006.n.031</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_19</td><td>BibArticle</td><td>Amato RJ, Sarao H. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. Clin Genitourin Cancer 2006;4:281&#8211;6.</td><td><a href=http://dx.doi.org/10.3816/CGC.2006.n.008>10.3816/CGC.2006.n.008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_19</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Thalidomide and Doxil in Patients with Androgen Independent Prostate Cancer (AIPC)</span>. <span style='background:#66FF66'>2008</span>. (Accessed August 25, 2008, at <span style='background:#FF3300'>http://www.clinicaltrials.gov</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25_19</td><td>BibArticle</td><td>Romero S, Stanton G, DeFelice J, Schreiber F, Rago R, Fishman M. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol 2007;25:284&#8211;90.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2006.09.017>10.1016/j.urolonc.2006.09.017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_19</td><td>BibArticle</td><td>Akakura K, Suzuki H, Ueda T, et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 2003;56:106&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/pros.10231>10.1002/pros.10231</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_19</td><td>BibArticle</td><td>Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439&#8211;43.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64163-8>10.1016/S0022-5347(05)64163-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_19</td><td>BibArticle</td><td>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29_19</td><td>BibArticle</td><td>Saika T, Kusaka N, Tsushima T, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol 2001;8:290&#8211;4.</td><td><a href=http://dx.doi.org/10.1046/j.1442-2042.2001.00302.x>10.1046/j.1442-2042.2001.00302.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_19</td><td>BibArticle</td><td>Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96&#8211;100.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19950701)76:1&lt;96::AID-CNCR2820760114&gt;3.0.CO;2-E>10.1002/1097-0142(19950701)76:1&lt;96::AID-CNCR2820760114&gt;3.0.CO;2-E</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_19</td><td>BibArticle</td><td>Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32_19</td><td>BibArticle</td><td>Di Lorenzo G, Autorino R, De Laurentiis M, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007;6:313&#8211;7.</td><td><a href=http://dx.doi.org/10.4161/cbt.6.3.3664>10.4161/cbt.6.3.3664</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_19</td><td>BibArticle</td><td>Chung F, Wang LC, Kestell P, Baguley BC, Ching LM. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemother Pharmacol 2004;53:377&#8211;83.</td><td><a href=http://dx.doi.org/10.1007/s00280-003-0753-2>10.1007/s00280-003-0753-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_19</td><td>BibArticle</td><td>Dreicer R, Klein EA, Elson P, Peereboom D, Byzova T, Plow EF. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 2005;23:82&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2004.08.013>10.1016/j.urolonc.2004.08.013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_19</td><td>BibArticle</td><td>Amato RJ, Hernandez-McClain J, Henary H. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate. Urol Oncol 2009;27(1):8&#8211;13.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2007.10.014>10.1016/j.urolonc.2007.10.014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_19</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Safety and Efficacy Study of GM-CSF</span>, <span style='background:#FFD9B3'>Thalidomide Plus Docetaxel in Prostate Cancer</span>. (Accessed August 25, <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>http://clinicaltrials.gov/ct2/show/NCT00450008</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37_19</td><td>BibArticle</td><td>Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer Biol Ther 2007;6:840&#8211;5.</td><td><a href=http://dx.doi.org/10.4161/cbt.6.6.4099>10.4161/cbt.6.6.4099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ning</span> <span style='background:#DDDDDD'>YM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gulley</span> <span style='background:#DDDDDD'>JL</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Arlen</span> <span style='background:#DDDDDD'>PM</span></span>, et al.</aug> <span style='background:#CCCCFF'>A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer</span>. <span style='background:#CCFF99'>J Clin Oncol</span> <span style='background:#66FF66'>2010</span>;<span style='background:#FFCC66'>28</span>:<span style='background:#D279FF'>2070&#8211;6</span>.</td><td><a href=http://dx.doi.org/10.1200/JCO.2009.25.4524>10.1200/JCO.2009.25.4524</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_19</td><td>BibArticle</td><td>Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discov 2007;2:167&#8211;74.</td><td><a href=http://dx.doi.org/10.2174/157489207780832478>10.2174/157489207780832478</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_19</td><td>BibArticle</td><td>Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56&#8211;63.</td><td><a href=http://dx.doi.org/10.1016/j.mvr.2005.01.002>10.1016/j.mvr.2005.01.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dahut</span> <span style='background:#DDDDDD'>W</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tohnya</span> <span style='background:#DDDDDD'>T</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Aragon-Ching</span> <span style='background:#DDDDDD'>J</span></span>, et al.</aug> <span style='background:#CCCCFF'>Phase I study of oral lenalidomide in patients with refractory metastatic cancer</span>. <span style='background:#CCFF99'>J Clin Pharmacol</span> <span style='background:#66FF66'>2009</span>;<span style='background:#FFCC66'>49</span>(<span style='background:#C8BE84'>6</span>):<span style='background:#D279FF'>650&#8211;60</span>.</td><td><a href=http://dx.doi.org/10.1177/0091270009335001>10.1177/0091270009335001</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, ArticleTitle, Author_FamilyName_1, Year, IssueID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR42_19</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Study of 2</span> Different Doses of Revlimid in Biochemically Relapse Prostate Cancer. (Accessed August 26, <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>http://clinicaltrials.gov/ct2/show/NCT00348595</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR43_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Phase</span> <span style='background:#DDDDDD'>II</span></span></aug> Study Evaluating Toxicity and Efficacy of Lenalidomide (Revlimid) in Chemotherapy-Naive Androgen Independent Prostate Cancer Patients. (Accessed 26 August, <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>http://clinicaltrials.gov/ct2/show/NCT00654186</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Garcia</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Triozzi</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Elson</span> <span style='background:#DDDDDD'>P</span></span>, et al.</aug> <span style='background:#CCCCFF'>Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial</span>. <span style='background:#CCFF99'>J Clin Oncol</span> 2008;26:abstr <span style='background:#66FF66'>5143</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR45_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Moss</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mohile</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shelton</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Melia</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Petrylak</span> <span style='background:#DDDDDD'>D.</span></span>, <span style='background:#BDBAD6'>A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). In:</span></aug> <span style='background:#66FF66'>2007</span> <span style='background:#FFD9B3'>Prostate Cancer Symposium; 2007</span>; <span style='background:#C0FFC0'>Orlando, FL</span>, <span style='background:#FFFF0F'>Abstract 89</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Pagliaro</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tannir</span> <span style='background:#DDDDDD'>N</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tu</span> <span style='background:#DDDDDD'>S</span></span>, et al.</aug> <span style='background:#CCCCFF'>A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy</span>. <span style='background:#CCFF99'>J Clin Oncol</span> <span style='background:#66FF66'>2008</span>;<span style='background:#FFFF0F'>26:Abstract 13545</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR47_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dreicer</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Garcia</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Smith</span> <span style='background:#DDDDDD'>S</span></span>, et al.</aug> <span style='background:#CCCCFF'>Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)</span>. <span style='background:#CCFF99'>J Clin Oncol</span> <span style='background:#66FF66'>2007</span>;<span style='background:#FFFF0F'>25:Abstract 15515</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR48_19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ketoconazole</span>, <span style='background:#DDDDDD'>Hydrocortisone</span></span>, and <span style='background:#BDBAD6'>Lenalidomide in Treating Patients with Prostate Cancer That Did Not Respond to Hormone Therapy. (Accessed August 26,</span></aug> <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>http://clinicaltrials.gov/ct2/show/NCT00460031</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>